Devises / KYMR
KYMR: Kymera Therapeutics Inc
46.18
USD
0.56
(1.20%)
Le taux de change de KYMR a changé de -1.20% aujourd'hui. Au cours de la journée, l'instrument a été échangé à un minimum de 46.00 et à un maximum de 47.30.
Suivez la dynamique Kymera Therapeutics Inc. Les cotations en temps réel vous aideront à réagir rapidement aux changements du marché. En basculant entre différentes périodes, vous pouvez surveiller les tendances et la dynamique des taux de change par minutes, heures, jours, semaines et mois. Utilisez ces informations pour prévoir les changements du marché et prendre des décisions de trading éclairées.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
KYMR Nouvelles
- Zacks Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
- Benzinga Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades' - iShares U.S. Financial ETF (ARCA:IYF), Gilead Sciences (NASDAQ:GILD)
- Investing Kymera Therapeutics stock price target lowered to $65 at Brookline Capital
- Investing Morgan Stanley initiates Kymera Therapeutics stock with Overweight rating
- Investing Kymera Therapeutics Q4 2024 slides: immunology pipeline advances with $600M cash infusion
- Investing Tuesday’s Insider Activity: Major Buys and Sells Shake Up Markets
- Investing Kymera Therapeutics (KYMR) director group buys $13.9 million in stock
- Investing Monday’s Insider Activity: Top Buys and Sells in US Stocks
- Investing Kymera Therapeutics: Baker Bros acquire $28.8m in shares
- Investing Kymera price target raised to $54 from $51 at BofA on pipeline updates
- Investing Kymera’s partnerships with Sanofi and Gilead drive value
- Investing Kymera Therapeutics Announces Pricing of $250 Million Public Offering
- Benzinga Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday - Apple (NASDAQ:AAPL), Alnylam Pharmaceuticals (NASDAQ:ALNY)
- Investing Kymera stock price target raised to $60 from $54 at H.C. Wainwright
- Investing Kymera Therapeutics price target lowered to $70 at Brookline Capital
- Investing Kymera Therapeutics launches $250 million public stock offering
- Investing Kymera Therapeutics stock falls after announcing $250 million offering
- Investing Kymera stock falls as Jefferies lowers price target on program shifts
- Seeking Alpha Kymera Shrugs Off Sanofi Bust With Gilead Deal - But There Are Caveats (NASDAQ:KYMR)
- Investing Kymera stock falls as Sanofi drops IRAK4 degrader for next-gen candidate
- Benzinga Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies - Gilead Sciences (NASDAQ:GILD), Sanofi (NASDAQ:SNY)
- Investing Sanofi to advance Kymera’s oral IRAK4 degrader KT-485 to clinical testing
- Seeking Alpha Tracking Baker Brothers Portfolio – Q1 2025 Update
- Investing Kymera at Goldman Sachs Conference: Pioneering Oral Protein Degraders
Range quotidien
46.00
47.30
Range Annuel
19.44
53.27
- Clôture Précédente
- 46.35
- Ouverture
- 46.74
- Bid
- 46.18
- Ask
- 46.48
- Plus Bas
- 46.00
- Plus Haut
- 47.30
- Volume
- 1.161 K
- Changement quotidien
- -1.20%
- Changement Mensuel
- 2.58%
- Changement à 6 Mois
- 20.89%
- Changement Annuel
- -0.86%
19 juillet, samedi